Although biliary atresia is not a common disease in pediatric surgery, it is not an uncommon disease, and its incidence is higher in Asia than in Western countries. 1. Efforts to reduce the age of surgery The age of biliary atresia surgery is still considered to be the most important factor affecting the survival rate of autologous liver, and reducing the age of surgery means early diagnosis, and early diagnosis mainly involves internists. In fact, in mainland China there are still a considerable number of physicians and surgeons who use more methods with unclear diagnostic value, delaying surgery. Therefore, it is strongly recommended that children with obstructive jaundice suspected of biliary atresia under 60 days of age should undergo direct caesarean or laparoscopic cholangiography to clarify the diagnosis. 2, further improve the success rate of surgery Kasai operation of biliary atresia belongs to the highest level of surgery in pediatric surgery, and its still the highest level of pediatric general surgeons, although it is not difficult for many highly experienced physicians to operate, but the efficacy does have a greater correlation with the operation, the key is the removal of the fibrous mass of the hepatic portal and the hepatic portal jejunostomy, and the appropriate depth and width of the clipped wound is the experience of each physician. My experience is that biliary atresia is a rare disease and the accumulation of experience in surgical operation is difficult for the individual physician, and once the initial radical treatment is not effective, it will affect the child for life. According to international opinion, biliary atresia is a rare disease and cases should be referred immediately to specialist physicians for treatment to obtain the best results, so biliary atresia in the UK is mainly referred to two large pediatric hepatobiliary disease centers for surgery (King’s Hospital, University of London and Birmingham Children’s Hospital, University of Birmingham). This experience is well worth learning from, at least hopefully units with <20 annual surgeries should be recommended for referral. Since the "Multicenter Comprehensive Diagnostic and Treatment Plan for Biliary Atresia" reported in the Chinese Journal of Pediatric Surgery in 2011, many specialized units have adopted this "hormonal-antibiotic-biliary preservation" approach for cases after radical biliary atresia surgery. Since the "multi-center comprehensive diagnosis and treatment program for biliary atresia" was reported, many specialized units have adopted this "hormone-antibiotic-antibiotic-liver protection" comprehensive treatment program for cases after radical biliary atresia surgery, and have indeed achieved certain results, mainly in the form of improved jaundice regression rate and decreased incidence of postoperative cholangitis. As a country with a large population and a high prevalence of biliary atresia, we should have the conditions and responsibility to conduct clinical multicenter studies on the postoperative treatment of biliary atresia, accumulate data, and propose a postoperative drug treatment plan for biliary atresia, a treatment plan for cholangitis, nutritional guidelines, and vaccination guidelines that are consistent with our national conditions. It is recommended to establish a multidisciplinary team (MDT) for the treatment of biliary atresia in specialized hospitals, mainly composed of pediatric surgeons, hepatologists and pediatric TCM physicians, to explore clinical pathways and individualized treatment plans to further improve postoperative pharmacological treatment. On the one hand, surgeons do not pay enough attention to outpatient follow-up, nor do they focus on data accumulation, let alone active follow-up; on the other hand, the high mobility of the domestic population and low compliance of family members result in a large number of missed visits, making it difficult to obtain a more accurate and realistic data. We are trying to establish a consultation and registration network for pediatric biliary atresia in China, which will facilitate medical health consultation for families, data collection and information exchange by specialists, and also for the accumulation of follow-up data. Sclera and generalized skin yellowing extrahepatic biliary atresia clay-colored stools